Venture capital firm Knife Capital has invested in Cape Town-based healthtech company Alignd, which plans to expand its value-based healthcare model into maternity and kidney care.
Lungi Nyathi, CEO of Alignd | image supplied
{{imaege}}
The investment, made through Knife Fund III, will support Alignd’s expansion beyond its existing palliative care programme into two areas where it aims to coordinate treatment around patient outcomes rather than the volume of services delivered.
Founded in 2018, Alignd develops programmes that bring patients, healthcare providers and medical schemes together, with payments linked to patient outcomes. Its model involves coordinating clinical teams and, where appropriate, delivering care in patients’ homes.
From palliative care to maternity and kidney health
Alignd began with palliative care, addressing a gap in private healthcare funding for patients nearing the end of life. While medical schemes have traditionally covered expensive hospital treatment, home-based support has received less attention.
The company has built a network of more than 500 providers delivering home-based, person-centred care.
According to Alignd, its programme has reduced non-beneficial chemotherapy in the final month of life by one-third. It also reports that two-thirds of patients die at home or in hospice, while 90% of families say they would recommend the service.
The company says its model has helped medical schemes save more than R600m, while enabling care providers to receive fairer reimbursement.
Alignd has partnerships with seven medical schemes, including Gems, Fedhealth and Bonitas. Its palliative care programme has an impact on more than 3.3 million lives, according to the company.
The new funding will help it extend the model into maternity care, through a programme connecting parents, healthcare providers